Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown origin.1 2 The epithelium of the large bowel is covered by a mucus gel layer. Mucus consists for about 5% of secretory mucins, which form the most important structural components in this gel layer. Generally, mucins are thought to consist of a protein backbone, with a large central region containing tandem repeats -that is, sequences of amino acids that are repeated several times in the protein. 3 These tandem repeats contain large numbers of serine and threonine residues, which are heavily 0-glycosylated. Terminally, negatively charged sialic acid and sulphate residues may be attached to the oligosaccharide chains, giving the mucins an overall negative charge. [4] [5] [6] To date, eight human mucin genes have been identified, designated MUC 1-8 and their coding sequences have been partially or completely determined.7-14 These mucin genes show tissue specific expression. Previously, we have shown that MUC2 is the most prominent secretory mucin in normal colon.15 MUC2 is synthesised as a high mannose N-glycosylated precursor of about 600 kDa, which is subsequently heavily 0-glycosylated, sulphated, and secreted. The mature mucin exhibits an aberrant mobility on sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) of approximately 550 kDa, while gel filtration showed that it was actually much larger. '5 It has been suggested that changes in mucin expression or composition could lead to a changed protective barrier function of mucus (reviewed in ref 16) . A number of changes in colonic mucus and mucin have been reported in association with UC. In active UC, the number of goblet cells, which synthesise the secretory mucins, are reduced and the mucus gel layer is thinner compared with mildly inflamed colon, independent of treatment.17 18 Concerning the 0-glycosylation of mucins, a reduction in mean number of sugar residues per oligosaccharide side chain has been reported,19 most probably resulting from premature termination of 0-glycosylation, leading to subsequent exposure of 'core-region' structures of the 0-linked oligosaccharides.5 20 Histochemically, a decrease in sulphomucins, with a reciprocal rise in sialomucins has been shown. [21] [22] [23] Some controversy still exists, however, regarding the staining techniques, because a comparative rise in either sialic acid or sulphate residues may change the balance of the staining pattern, independent of the exact number of these residues.22 24 Nevertheless, sialic acid residues seem to be increased, with loss of 0-acetyl substitutions.2426 As only 0-glycosylation was studied and not the underlying mucin gene expression, it was unclear, whether the abnormalities in 0-glycosylation result from changed post-translational processing or from changes in expression of different mucins. In fact, until recently, it was unknown which mucins were expressed in colon and whether the expression of these mucins was changed in UC.
In this study, our goal was to determine if MUC2 was also the major mucin in colon affected by UC and to compare mucin biosynthesis qualitatively. Therefore, we used the same isolation procedures as for normal human colonic mucin (HCM) to independently isolate mucin from colon affected by UC, referred to as human colitic colonic mucin MUC2 is the prominent colonic mucin expressed in ukerative colitis (HCCM). Amino acid and carbohydrate compositions of HCM and HCCM were compared and a polyclonal antiserum was raised against HCCM to study the mucin biosynthesis in UC colonic biopsy specimens. Mucin biosynthesis in UC colon was then compared with biosynthesis of mucin in normal colonic tissue. Moreover, mucin expression in normal and UC colon was independently determined by northern blotting, using DNA probes representing MUC 1-6. [35S] sulphate pulse labelling, when the medium containing the radioactive label was exchanged for Eagle's minimal essential medium without label, supplemented with 0.5 mM methionine (Sigma) and 0 1 mM cysteine (Sigma). Specimens were homogenised in homogenisation buffer containing 50 mM TRIS, pH 7 5, 5 mM EDTA, 1% (wt/vol) Triton X-100 (BDH), 100 ,ug/ml pepstatin A (Sigma), 100 ,ug/ml leupeptin (Sigma), 1 mg/ml soybean trypsin inhibitor (Sigma), 0-24 U/ml aprotinin (Sigma), and 1 mM phenylmethylsulphonyl fluoride (Sigma). Mucin was immunoprecipitated from labelled homogenates or from chase medium overnight at 4°C, using 30 gl anti-HCCM, anti-HCM or anti-MRP. The immunocomplexes were precipitated using protein A coupled to Sepharose C1-4B. Immunoprecipitated mucin was analysed on 3% stacking/4% running SDS-PAGE, which was stained with PAS and subsequently fluorographed. For molecular weight markers, unreduced [35S]amino acids labelled rat gastric mucin precursor was used, with molecular mass of 300 kDa for the monomer and 600 kDa for the dimer38 and prestained high molecular weight markers, with molecular masses between 49.5 to 205 kDa (BioRad).
Methods
Northern blot analysis MUC1 (about 450 bp), MUC2 (about 900 bp), and MUC3 (about 400 bp) sequences, cloned in the EcoRl site of pBluescript (Stratagene), have been described.8 9 39 40 pUC19 containing MUC5A/C (about 1700 bp) sequence was kindly provided by Dr L Klomp.41 MUC4 (48 bp) sequence was obtained by a standard polymerase chain reaction procedure42 using MUC4 gene specific primers (see later) and an antisense MUC4 oligonucleotide as template. This template was kindly provided by Dr H Vos and is based on the sequence published by Porchet of 5 'GTCGGTGACAGGAAGAGGGGTGG-CGTGACCTGTGGATGCTGAGGAAGT 3Y.10 MUC6 DNA (about 260 bp) was also obtained by a polymerase chain reaction using MUC6 gene specific primers (see later) and human genomic DNA as template. After amplification MUC4 and MUC6 DNA fragments were digested with EcoRl and Sall and separated on a 2.5% agarose gel by standard procedure.42 Subsequently, the DNA fragments were isolated from the gel using Qiaex gel extraction kit (Qiagen, Chatsworth, CA, USA) as described by the manufacturer, and cloned in the corresponding sites of pBluescript. Sequences were verified by sequence analysis using Sequenase 2.0 (USB, Cleveland, OH, USA) as described by the manufacturer. All DNA probes used for northern blot analysis were obtained by digestion of the appropriate restriction enzymes and separation on agarose gels by standard procedure.42 The DNA probes were isolated using the Qiaex gel extraction kit, and labelled with at-32P-dATP by the random prime labelling procedure.42 All probes were first tested and showed positive reaction with corresponding mRNA.
There follows the oligonucleotides in which the engineered EcoRI (GSP-1) and Sall (GSP-2) restriction sites are underlined.
MUC4 GSP-1: 5'GGAATTCGTCGGT-GACAG 3'. MUC4 GSP-2: 5'CTCTGTC-GACTTCCTCAG 3'. MUC6 GSP-1:
RNA was isolated from four sigmoidal biopsy specimens per patient, using the RNeasy total RBA kit (Qiagen), according to manufacturer's protocol. RNA samples (5 ,ug) (Table) . Similar to HCM, the sialic acid content in HCCM is very high. When colonic homogenates were analysed on reducing SDS-PAGE, and stained with PAS, one high molecular weight product could be visualised (Fig IA) . This PAS stained band is present in both normal and UC tissue homogenates. Moreover, the molecular weights of these PAS stained bands in tissue .homogenates are comparable with purified HCM as well as purified HCCM stained by PAS (Fig 1, A and B) . This shows that normal and UC colonic mucin are both visible by PAS staining on low percentage SDS-PAGE as one high molecular weight band, migrating to a similar position in the gel, being virtually the only product visible in PAS stained tissue homogenates.
Heavy O-glycosylation is known to protect the large central part of the polypeptide of mucins against proteolytic degradation.3 This proteinase K resistant central part of the mucin is referred to as the glycopeptide. In contrast, the C-and N-terminal protruding parts of the protein are far less glycosylated, rendering these parts susceptible to proteolytic degradation.3 Proteinase K digestion of either HCM or HCCM resulted in only a slight shift in mobility of both PAS stained mucin bands (Fig 1) . Thus, a very large part of the mucin molecules, most probably representing the glycopeptide, remained intact as visualised by the similar intensity of PAS staining, showing that only the comparatively small proteinase K sensitive parts of the mucin were digested. Part of the gel, containing identical samples, was used for western blotting. Anti-HCCM, raised against purified HCCM, reacted mainly with a high molecular weight band of similar mobility as the PAS stained bands, in normal as well as UC homogenates (Fig 1) . Anti-HCCM reacted further with similar high molecular weight bands, in the purified preparations of HCM as well as HCCM. The recognition of the high molecular weight mucin is lost after proteinase K digestion, although the PAS staining shows that the proteinase K resistant mucin glycopeptides are still intact (Fig 1) . As only the small protruding, relatively unglycosylated peptide parts were cleaved off by proteinase K, this suggests first that anti-HCCM mainly recognises peptide epitopes on the mucins and secondly, that HCM and HCCM share common peptide epitopes. To some extent the anti-HCCM antiserum also recognises bands of lower molecular weights in homogenates of both normal and UC colon.
Specificity of anti-HCCM was further studied using immunohistochemistry on tissue sections of a biopsy specimen from a patient with clinical and endoscopic mildly active UC. Haematoxylin and azofloxin staining shows a mildly active UC, with crypt distortion and neutrophilic infiltrate (Fig 2A) . Alcian blue and nuclear fast red staining of an adjacent tissue section (Fig 2B) 35 
S-AA PAS Two biopsy specimens, taken from the same ------------------------------
-patient described in Fig 2, high similarity (Fig 5A) . This was also shown on mRNA level. On northern blot analysis, strong hybridisation could be seen, using a MUC2 probe, both for RNA isolated from healthy as well as UC colonic biopsy specimens. In contrast, little hybridisation could be detected using a MUC4 probe and virtually no hybridisation with MUC1, MUC3, MUC5, and MUC6 probes.
This shows, that MUC2 remains the major mucin expressed in colon of patients with UC compared with controls.
Raising polyclonal antisera against the protruding peptide parts of mucin proves essential in studying biosynthesis of mucins, as these antisera will be able to recognise not only the precursor protein, but also the mature glycoprotein, independent of the degree of 0-glycosylation, as we have described.28 38 48 Previously, we became clear that mature HCM was far larger than 550 kDa, so the mobility of HCM on SDS-PAGE was concluded to be anomalous. 15 In this respect it is interesting that we previously were able to show that rat colon prominently expresses a MUC2 homologue.48 The biosynthesis of this rat colonic MUC2 is very similar to the human colonic MUC2: the rat MUC2 precursor is approximately 600 kDa and the secreted precursor has an anomalous mobility of approximately 650 kDa on SDS-PAGE. The molecular mass of mature rat MUC2 was shown by gel filtration to be much greater than 650 kDa.48 The reasons for this anomalous mobility are not completely clear. However, we have shown for HCM15 and for rat MUC248 as well as for HCCM (data not shown), that these mucins show very similar mobilities on PAGE, independent of saturation with SDS, indicating that mobility of these mucins is intrinsically determined and may in part result from their high negative charge.49
In UC, MUC2 is also synthesised as a 600 kDa precursor. Restriction fragment length polymorphism has been described for the MUC2 gene, caused by variation in the number of tandemly repeated amino acid sequences.50 In all our studies, however, either with biopsy specimens from healthy controls as well as from UC patients, we always detected MUC2 biosynthetically as one, rather sharp delineated band of about 600 kDa. So far, we have no clear explanation for the discrepancy between the described variation in length of the MUC2 gene and the absence of size variation ith the MUC2 protein product. It may be that the SDS-PAGE gels used have a too small resolution within the high molecular mass ranges to detect differences in molecular mass. After glycosylation and sulphation MUC2 acquired a slightly higher mobility on SDS-PAGE of approximately 550 kDa. Only the 550 kDa glycoprotein, which was sulphated, was secreted into the medium. The difference in mobility between the precursor of 600 kDa and the mature mucin with an apparent molecular mass of 550 kDa was small, but was always, although at times difficult, visible in five separate experiments with UC biopsy specimens. As the mobility of mature colonic MUC2 is anomalous on SDS-PAGE, it is very difficult to study differences in glycosylation using this technique.
In contrast with other studies, which found a showed, that sulphation does not seem to be changed dramatically in UC. As biopsy specimens are known to differ in size, however, it is premature to make firm conclusions on quantities of MUC2.
In conclusion, when isolating colonic mucin from colon affected by UC, MUC2 is predominantly isolated. Moreover, MUC2 biosynthesis does not seem to be qualitatively changed, compared with MUC2 synthesis in healthy colon. Quantitative studies are presently being undertaken, however, to examine possible changes in the rate of biosynthesis, secretion, and structure.
